Summing up, the new third generation NS3/4A protease inhibitors in combination with other DAAs can be a substantial step in the eradication of HCV in the so called difficult-to-treat population (e.g. compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment). This evidence concerns the gene KRAS and stage 5 chronic kidney disease.